Health Advisory: Minnesota Resource Allocation Platform (MNRAP) Launch

Minnesota Department of Health, Tue, Feb 9 09:00 CST 2021

Action Steps

Local and tribal health department: Please forward to hospitals, clinics, urgent care centers, emergency departments, and convenience clinics in your jurisdiction.
Hospitals, clinics and other facilities: Please forward to infection preventionists, infectious disease physicians, emergency department staff, hospitalists, primary care clinicians, and all other health care providers who might see patients with COVID-19.
Health care providers:

- Use Minnesota Resource Allocation Platform (MNRAP) to determine if adult patients with mild to moderate COVID-19 should be treated with monoclonal antibodies, including:
    - bamlanivimab (Eli Lilly)
    - casirivimab/imdevimab (Regeneron)
- Work with patients to complete the screening OR ask patients to complete it on their own. The system will equitably allocate and refer patients to an infusion site.
- Report COVID-19/SARS-CoV-2 Infections (https://www.health.state.mn.us/diseases/coronavirus/hcp/report.html) within one working day by phone to 651-201-5414 or 877-676-5414 or using the COVID-19 Case Report Form (https://www.health.state.mn.us/diseases/coronavirus/hcp/covidreportform.pdf).

Background

MDH is launching the Minnesota Resource Allocation Platform (MNRAP) system, which is an instant read lottery screener to determine eligibility for monoclonal antibody (mAb) therapy, refer patients to an infusion site, and promote equity. Patients will indicate if they belong to a health system and allow them to choose the site best suited for them. Referrals made by MNRAP are provisional and final clinical judgement remains with the infusion site to determine eligibility and scheduling. Pediatric patients are not included in the MNRAP platform. Anyone under the age of 18 years should work with their provider to determine eligibility.

The link to MNRAP (which went live on Monday, February 8th) can be found here: https://www.health.state.mn.us/diseases/coronavirus/mnrap.html

The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on November 9, 2020, to permit the emergency use of the investigational monoclonal antibody (mAb) therapy bamlanivimab and November 21 for casirivimab/imdevimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients (patients age 12 and more who weigh 40 kg and more) who are at high risk for severe disease due to age or certain medical conditions. The EUA notes that neither bamlanivimab nor casirivimab/imdevimab is authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19.

Getting this therapy to the proper patients is time-sensitive because mAb must be given as soon as possible after a positive COVID-19 test result and within 10 days of a person showing symptoms. The MNRAP system will help both clinicians and patients determine if a) they are eligible to receive the therapy and b) increase awareness of where eligible patients can receive this therapy.

For More Information

- MDH Therapeutic Options for COVID-19 Patients: https://www.health.state.mn.us/diseases/coronavirus/hcp/therapeutic.html
- Call MDH at 651-201-5414 or 877-676-5414.

A copy of this HAN is available at: MDH Health Alert Network (http://www.health.state.mn.us/han) The content of this message is intended for public health and health care personnel and response partners who have a need to know the information to perform their duties.